AbbVie Targets Mylan In Latest Effort To Shield Norvir Patents

Law360, New York (June 17, 2013, 8:18 PM EDT) -- AbbVie Inc. on Friday accused Mylan Pharmaceuticals Inc. of violating three of its patents by attempting to market a generic version of the HIV drug Norvir, according to a suit filed in Delaware federal court.

In its most recent attempt to maintain a hold on the HIV treatment market, AbbVie claims that Mylan's abbreviated new drug application for generic ritonavir capsules infringes on patents covering Norvir's pharmaceutical composition and formulation.

The complaint states that Mylan's infringement of the AbbVie patents will cause "irreparable harm" and seeks a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.